{"name":"Epigenetix, Inc.","slug":"epigenetix-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxPdGszdTN1MTl6bG0xVmUweWlweVg5Rm9LQkd4WUpyY0VRQzhRQkxjcVlGSC1CdDUxV3hLVXhla0JUcGVLbDkwWXdmYmppVmZOV0RENVBEamZrWUw1QW1ZVjhCYjc2ZVBMYkRrYTBZa09XcXllaVFNelZJUk9fVXJzSEZuWGN2bnl6TGhLUDdJNGJmQjdYdThfNFZIdS1qWkdFdmQ2NzE3eS1ZZnplQ0w5WDdJanRMOUNJSXhuVkthbGlSdXhLNjVXaGFCWEh4bVN3OUs4V19FX2U1aGpPakRwSHRkM0tIVHBCUUs5Nm8wVXYyN18yMWpLNXlpUHhpUFE3UG10S3BrbkNtRXF5N3JncXlidWR6Rnox?oc=5","date":"2021-11-02","type":"pipeline","source":"GlobeNewswire","summary":"Cambridge Epigenetix Raises $88 Million Series D Financing - GlobeNewswire","headline":"Cambridge Epigenetix Raises $88 Million Series D Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxOY2dYX3dkZEZCRTZHT0tQYVUwVnZMQ3BfSHM1eDdkTDMwZzAwZmlWcm96ZW40ZENFUzhpbmtxelJ1THdKXzlHRUpxaHFKTHpPS3B4X3J1azJwX0czQ2o2bFV3VmVPbWRYb0ZHcnNhWXRlVEM5T2tmNVJRR19SNHZFT19pdzRZcGdUUzNaTzRVYXM2Q2JmbUkwMUY1QWtPcUpUQjU3ZG1qZVU0ZEhheTU3dlVIbWFYYm8tdVBEZ211el9ESXpUOXpGSG5fc196UnVLVkNyeWE3Z2VNOGdNSHVQWGpwUWxtbGxjQlpqcVJFNTlqUVowdUFfbm9mV0dwMmZOUHFkcDZ0aTBLTW9Ed0NxbkQzVHZJbTJmQ3FpYV9OVkVzOW9vNnRWNzNvSzREQU1FZnExVHZyY1oxenl5VURhNVpnckF4alV1RkJLYTlza0xZYWdFM1RkUHA0a3FNZzA?oc=5","date":"2018-02-28","type":"pipeline","source":"newswire.ca","summary":"NEOMED Institute Launches NEOMED Therapeutics 1 Inc. to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound - news","headline":"NEOMED Institute Launches NEOMED Therapeutics 1 Inc. to fund and develop a dual BET inhibitor anticancer therapy pipelin","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}